Gendicine works by combining the p53 gene, which is a tumor suppressant, with a utility virus. When the Gendicine virus is then injected into the cancerous tumor, the virus inserts the p53 gene into the cancer cells. Once the p53 gene is in the cancer cells, it causes them to self destruct. Clinical trials have shown a 64% success rate in this therapy combined with radiation therapy.
Dr. Li Dinggang is one of the men responsible for the success of this new therapy. He is an oncologist that studied for five years at the Johns Hopkins University during the 1990’s. Since 1997, he has partnered with Dr. Peng Zhaohui, the chairman and CEO of the Chinese pharmaceutical company, SiBiono, to develop Gendicine. At 50 years old, Dr. Dinggang is the director of the Gene Therapy Center in China and also actively treats cancer patients at the Haidan Hospital in Beijing.
Dr Dinggang requests that any cancer patients that are interested in Gendicine therapy submit their medical case histories in English and he will have it translated to Chinese. After reviewing the case history in Chinese, he will reply back with an assessment as to whether you should proceed to seek admission into the Haidan hospital for treatment.
It is advisable to seek out a friend or someone you know that is fluent in Chinese, to help with seeking admission to the hospital and basically communicating with the administration staff. Also, a Chinese translator would be very helpful in organizing local transportation and interim accommodation requirements while in Beijing.